Central role of transforming growth factor type beta 1 in skeletal muscle dysfunctions: An update on therapeutic strategies

Johanna Abrigo, Felipe Simon, Daniel Cabrera, Gonzalo Córdova, Capucine Trollet, Claudio Cabello-Verrugio*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Among the soluble factors that regulate skeletal muscle function, Transforming Growth Factor type Beta 1 (TGF-β1) is one of the most studied. This factor inhibits myogenesis and regeneration by regulating the activity and function of satellite cells (SCs). Indeed, TGF-β has a central role in muscle pathologies in which there is development of fibrosis and/or atrophy of skeletal muscle. Thus, in this review we present the critical and recent antecedents regarding the mechanisms and cellular targets involved in the effects of TGF-β1 in the muscle, in pathological processes such as the inhibition of regeneration, fibrosis and atrophy. In addition, an update on the development of new strategies with therapeutic potential to inhibit the deleterious actions of TGF-β in skeletal muscle is discussed.

Original languageEnglish
Pages (from-to)1189-1200
Number of pages12
JournalCurrent Protein and Peptide Science
Volume19
Issue number12
DOIs
StatePublished - 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 Bentham Science Publishers.

Keywords

  • Blocking antibodies
  • Dystrophy
  • Fibrosis
  • Muscle atrophy
  • Renin angiotensin system
  • Therapy

Fingerprint

Dive into the research topics of 'Central role of transforming growth factor type beta 1 in skeletal muscle dysfunctions: An update on therapeutic strategies'. Together they form a unique fingerprint.

Cite this